Given the recent increase in nirsevimab supply and the manufacturers’ plan to release an additional 230,000 doses in January, CDC advises health care providers to return to recommendations put forward in August 2023 by CDC and the Advisory Committee on Immunization Practices (ACIP) on use of nirsevimab in young children. Nirsevimab (Beyfortus, Sanofi and AstraZeneca) is recommended for preventing lower respiratory tract disease in young children associated with RSV. Infants and children recommended to receive nirsevimab should be immunized as quickly as possible. Health care providers should not reserve nirsevimab doses for infants born later in the season when RSV circulation and risk for exposure to RSV may be lower.
Following are additional CDC resources:
• Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023–2024
• Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season